Targeting androgen receptor and Wnt pathway in endocrine-resistant breast cancer.

VIRGINIA FIGUEROA ; GABRIELA PATACCINI; MARTÍN ABBA; ANA SAHORES; CLAUDIA LANARI; CAROLINE LAMB

Mar del Plata

Congreso; Reunión anual de sociedades de Biociencia SAIC SAFE SAB SAP; 2019

Endocrine therapy is the standard treatment for patients with luminal breast cancer. However, after treatment most patients develop hormone resistance, by mechanisms that may include deregulation of growth factor signaling pathways. Fibroblast growth factor 2 (FGF2) consists of a secreted low molecular weight form (LMW-FGF2) and several nuclear high molecular weight forms (HMW-FGF2). We previously demonstrated that FGF2-overexpression in endocrine responsive T47D cell lines, induced hormone resistance. The aim of this study was to explore the mechanisms underlying endocrine resistance. By RNAseq, we compared LMW- and HMW-FGF2-T47D cells, with T47D cells transfected with an empty vector (T47D-ctrl) and found that FGF2 overexpressing cells had a deregulated WNT signaling pathway with the upregulation of several WNT ligands. We also detected decreased estrogen receptor α and progesterone receptors (PR) along with an increase in androgen receptors (AR), both at the mRNA and protein levels. We found a more pronounced decrease of PR isoform A (PRA) than isoform B (PRB) resulting in a low PRA/PRB ratio, which is consistent with an endocrine resistant phenotype, according to previous results from our lab. To explore the role of AR and WNT signaling pathways in FGF-triggered endocrine resistance, we evaluated the effect of dihydrotestosterone (DHT, AR agonist), enzalutamide (E, AR antagonist) and LGK974 (WNT inhibitor) in LMW- and HMW-FGF2-T47D cells compared with T47D-ctrl cells. In endocrine resistant cells, DHT induced cell proliferation while blocking AR and WNT pathways inhibited cell proliferation and tumor growth. Conversely, DHT inhibited T47D-ctrl cell proliferation and blocking the AR had no significant effect on tumor growth. Our results suggest that targeting AR and/or WNT pathways may be an alternative therapy for endocrine-resistant breast carcinomas with low PR and high AR levels.